SCHEMBL31676143

SCHEMBL31676143

Cn1ccc(-c2cc(OC[C@@H]3CNCCCO3)c3cccnc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 12/20 0.48
▸ EPHA2 P29317 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ EPHB4 P54760 1/20 0.41
▸ HTR2A P28223 2/20 0.41
▸ SLC6A4 P31645 2/20 0.41
▸ ADRB2 P07550 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ ADRA2C P18825 1/20 0.41
▸ IRAK4 Q9NWZ3 3/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30613585 0.94 SYK (0.49) SYKEPHA2HTR2ASLC6A4ADRB2
SCHEMBL31676298 0.90 SYK (0.45) SYKEPHA2KDREPHB4HTR2A
SCHEMBL31676085 0.85 SYK (0.48) SYK
SCHEMBL31676346 0.85 SYK (0.49) SYKEPHA2HTR2ASLC6A4ADRB2
SCHEMBL31676118 0.85 SYK (0.48) SYK
SCHEMBL31676189 0.84 SYK (0.49) SYK
SCHEMBL31676122 0.84 SYK (0.46) SYKEPHA2KDREPHB4IRAK4
SCHEMBL31676186 0.84 SYK (0.47) SYKEPHA2HTR2ASLC6A4ADRB2
SCHEMBL31676093 0.84 IRAK4 (0.47) SYKHTR2ASLC6A4ADRB2HTR1A
SCHEMBL31676198 0.84 SYK (0.47) SYKEPHA2KDRHTR2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2025-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS LCK, BTK, SYK SYK 3/4885EPHA2 1019/4885KDR 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback